Last updated: November 12, 2026
Alogliptin benzoate/metformin hydrochloride, marketed in the United States as Kazano by Takeda Pharmaceuticals, is a fixed-dose combination of a DPP-4 inhibitor and metformin. Its commercial position has weakened as diabetes prescribing shifted toward GLP-1 receptor agonists and SGLT2 inhibitors, while generic DPP-4 competition reduced pricing power. The product has no separately reported public revenue stream, and Takeda does not generally disclose Kazano sales as a standalone line item.
The combination remains clinically relevant for patients requiring oral glucose-lowering therapy, but its commercial outlook is mature to declining. The primary risks are class substitution, generic entry, limited differentiation, and the loss of premium pricing for alogliptin-containing products.
What is alogliptin benzoate/metformin hydrochloride?
Alogliptin benzoate/metformin hydrochloride combines:
| Component |
Drug class |
Primary role |
| Alogliptin benzoate |
DPP-4 inhibitor |
Increases glucose-dependent incretin activity |
| Metformin hydrochloride |
Biguanide |
Reduces hepatic glucose production and improves insulin sensitivity |
The U.S. product is Kazano, supplied in immediate-release tablets containing either 12.5 mg alogliptin/500 mg metformin or 12.5 mg alogliptin/1,000 mg metformin. The product is indicated as an adjunct to diet and exercise for adults with type 2 diabetes when treatment with both components is appropriate.[1]
Alogliptin is also marketed in other formulations:
| Product |
Active ingredients |
U.S. status |
| Nesina |
Alogliptin benzoate |
Approved alogliptin monotherapy |
| Kazano |
Alogliptin benzoate/metformin hydrochloride |
Approved fixed-dose combination |
| Oseni |
Alogliptin/pioglitazone |
Approved fixed-dose combination |
The product is not a biologic and has no biosimilar pathway. Competitive pressure comes from generic small-molecule products and therapeutic substitution rather than biosimilar entry.
What is the FDA regulatory status of Kazano?
The FDA approved Kazano in January 2013 under New Drug Application 022910.[1] Approval was based on the established efficacy of alogliptin and metformin, together with clinical data supporting the fixed-dose combination.
Kazano carries class- and component-specific safety considerations:
- Lactic acidosis risk associated with metformin, particularly in patients with significant renal impairment.
- Pancreatitis warnings associated with alogliptin.
- Heart-failure risk language for alogliptin based on cardiovascular safety findings.
- Renal-dose considerations for alogliptin and metformin.
- Vitamin B12 deficiency risk associated with long-term metformin use.
- Contraindications or restrictions in severe renal impairment and selected acute clinical conditions.
FDA labeling requires renal-function assessment before and during treatment. The product is therefore less attractive than some newer therapies for patients with chronic kidney disease, heart-failure risk, or a need for cardiovascular and renal outcome benefits.[1][2]
What is the clinical positioning of the combination?
Kazano is positioned as an oral escalation option for patients inadequately controlled on metformin or alogliptin alone. Its value proposition is convenience rather than a new mechanism. The combination can reduce pill burden, but it does not provide the weight loss, cardiovascular outcome profile, or renal protection increasingly associated with GLP-1 and SGLT2 therapies.
When does alogliptin/metformin lose exclusivity?
Alogliptin’s original U.S. chemical patent protection was tied to the Takeda alogliptin patent family. The principal compound patent protection expired in the 2020s, while later combination and formulation patents extended protection for selected alogliptin/metformin products.
The commercial exclusivity timeline is best summarized as follows:
| Milestone |
Approximate timing |
Commercial effect |
| FDA approval of Kazano |
January 2013 |
U.S. launch |
| New chemical entity exclusivity for alogliptin |
Through approximately 2018 |
Delayed certain ANDA approvals |
| Core alogliptin patent expiry |
2023-era |
Opened the market to generic alogliptin products |
| Later combination patent expiry |
2028-2029-era, subject to Orange Book status and patent-term adjustments |
Potentially delayed unrestricted generic substitution for specific combinations |
| Post-patent market |
Late 2020s onward |
Price competition and therapeutic substitution |
The Orange Book remains the controlling source for current U.S. patent listings and expiration dates. The listed patent estate has historically included patents covering alogliptin compounds and fixed-dose compositions.[3] Patent-term adjustment, pediatric extensions, terminal disclaimers and later Orange Book changes can affect the effective date for an ANDA applicant.
What patents protect alogliptin/metformin?
The patent estate has generally included two layers:
- Compound patents covering alogliptin or related pyrimidinedione derivatives.
- Combination or composition patents covering alogliptin with metformin and specific dosage forms.
The compound patents are commercially less important after expiration because generic manufacturers can compete with alogliptin-containing products. Combination patents have greater relevance to Kazano because they may delay approval or marketing of an identical fixed-dose combination even after basic alogliptin protection expires.
Patent protection does not prevent therapeutic substitution with sitagliptin/metformin, linagliptin/metformin, saxagliptin/metformin or non-DPP-4 therapies.
Are there Paragraph IV challenges to Kazano?
Publicly visible patent risk for Kazano is lower than the risk faced by large blockbuster products such as Januvia, Jardiance or Ozempic. The market has not produced a widely reported, high-value Paragraph IV litigation campaign centered on Kazano comparable with the litigation surrounding leading DPP-4 or GLP-1 products.
Potential ANDA strategies include:
- Challenging expired or invalid alogliptin compound claims.
- Declaring non-infringement of combination patents.
- Filing a Paragraph IV certification against listed fixed-dose patents.
- Entering after patent expiry under a Paragraph III certification.
- Marketing separate alogliptin and metformin tablets instead of an identical fixed-dose product.
A Paragraph IV filing would create litigation risk for the patent holder, but the economic incentive is limited by the relatively small branded market and intense generic competition. The expected value of litigation is therefore lower than for a high-revenue product with substantial remaining exclusivity.
What is the Orange Book status of alogliptin/metformin?
Kazano was listed in the FDA Orange Book as an approved fixed-dose combination product. Orange Book analysis should distinguish among:
- The reference listed drug for the combination.
- Patent listings directed to alogliptin.
- Patent listings directed to alogliptin/metformin compositions.
- Any use codes associated with approved treatment methods.
- The discontinued or active commercial status of the reference product.
A listed patent does not establish validity or enforceability. It determines the certification obligations for an ANDA applicant. Generic applicants can challenge listed patents, carve out patented uses, or wait for expiration.
The commercial impact of any remaining patent is also reduced if physicians and payers can substitute an approved alogliptin product, metformin, or another DPP-4 inhibitor.
How strong is the patent estate for Kazano?
The estate is moderate in formal scope but weak in commercial leverage.
| Factor |
Assessment |
Reason |
| Compound protection |
Mature or expired |
Core alogliptin protection is no longer a long-duration barrier |
| Combination protection |
More relevant |
Fixed-dose alogliptin/metformin claims may extend into the late 2020s |
| Formulation differentiation |
Limited |
Immediate-release tablets have limited technical complexity |
| Manufacturing barrier |
Low to moderate |
Both active ingredients are established small molecules |
| Regulatory barrier |
Moderate |
ANDA development requires bioequivalence and quality controls |
| Litigation value |
Limited |
Small market and strong therapeutic substitution |
| Biosimilar protection |
Not applicable |
Product is a small-molecule drug |
| Overall commercial exclusivity |
Weakening |
Generic and class-level competition dominate |
The main residual barrier is not manufacturing complexity. It is the combination of patent certification, bioequivalence requirements, supplier qualification and limited economic return.
What formulations are protected by alogliptin/metformin patents?
The principal commercial formulation is an immediate-release oral tablet. Combination patents may cover:
- Alogliptin and metformin in specified ratios.
- Particular dosage strengths.
- Pharmaceutical compositions containing the two active ingredients.
- Processes for preparing or formulating the combination.
- Treatment methods using the fixed-dose product.
A generic company may avoid some formulation claims by marketing separate tablets or by using a different formulation design. That approach sacrifices the convenience advantage of the fixed-dose product but can reduce patent exposure.
Extended-release or modified-release metformin products are subject to separate technical and regulatory considerations. A product combining alogliptin with extended-release metformin would not automatically be interchangeable with Kazano.
How has the financial trajectory developed?
Kazano’s financial trajectory follows the broader decline of the DPP-4 inhibitor market.
Launch and growth phase
Following its 2013 approval, Kazano benefited from:
- The established use of metformin as first-line therapy.
- Physician familiarity with DPP-4 inhibitors.
- A need for oral combination products.
- Takeda’s commercial infrastructure for diabetes medicines.
- A relatively favorable tolerability profile compared with therapies associated with hypoglycemia or weight gain.
The product did not become a major global revenue driver on the scale of leading DPP-4 products. It competed against Januvia, Janumet, Onglyza, Tradjenta and other products with larger commercial footprints.
Maturity phase
From the mid-2010s onward, the market shifted toward products with demonstrated cardiovascular, renal or weight-loss advantages. DPP-4 inhibitors remained useful because of oral administration, low hypoglycemia risk and tolerability, but their growth slowed.
Kazano faced four structural pressures:
- Therapeutic substitution. GLP-1 receptor agonists and SGLT2 inhibitors captured treatment growth.
- Portfolio competition. Other DPP-4/metformin combinations had stronger brand recognition or greater formulary presence.
- Limited differentiation. Alogliptin did not establish a strong clinical advantage over competing DPP-4 inhibitors.
- Generic erosion. Once component and combination patents weakened, price competition increased.
Current financial position
Takeda’s public reporting has not generally provided a separate Kazano revenue line. Sales are typically aggregated within broader diabetes, product or geographic categories. As a result, no reliable public annual revenue series exists for Kazano alone.
The appropriate financial conclusion is:
- Kazano is a mature, non-core product.
- Standalone revenue is not publicly quantifiable from Takeda financial statements.
- The product’s value is substantially lower than during its protected launch period.
- Future revenue is more likely to decline through generic substitution and formulary displacement than to recover through volume growth.
- Manufacturing and licensing value depends on low-cost supply, geographic rights and access to markets where DPP-4 therapy remains widely used.
Takeda’s strategic focus has moved toward oncology, gastroenterology, rare diseases, plasma-derived therapies and vaccines. That portfolio direction reduces the probability that Kazano will receive major new investment or commercial repositioning.[4]
Which companies are challenging the alogliptin/metformin market?
Competition comes from both direct and indirect competitors.
Direct fixed-dose competitors
| Product |
Company or originator |
Mechanism |
| Janumet |
Merck |
Sitagliptin/metformin |
| Kombiglyze XR |
AstraZeneca |
Saxagliptin/metformin |
| Jentadueto |
Boehringer Ingelheim/Eli Lilly |
Linagliptin/metformin |
| Kazano |
Takeda |
Alogliptin/metformin |
| Generic combinations |
Multiple manufacturers |
DPP-4 inhibitor/metformin combinations |
Therapeutic substitutes
The strongest commercial substitutes are:
- Semaglutide and other GLP-1 receptor agonists.
- Dulaglutide and injectable incretin therapies.
- Empagliflozin, dapagliflozin and other SGLT2 inhibitors.
- Insulin and basal insulin combinations.
- Sulfonylureas and thiazolidinediones in cost-sensitive markets.
Alogliptin/metformin is most exposed where formularies prioritize cardiovascular outcomes, weight reduction, renal protection or overall treatment intensification.
What generic launch scenarios exist?
Three generic-entry scenarios are commercially plausible.
Scenario 1: Component substitution
Generic alogliptin and generic metformin are prescribed as separate tablets. This is the simplest route for payers and may occur before a fully substitutable fixed-dose product achieves broad distribution.
Scenario 2: Fixed-dose generic entry
A manufacturer launches a generic equivalent to Kazano after satisfying patent and regulatory requirements. This creates direct price competition and accelerates brand erosion.
Scenario 3: Therapeutic displacement
Payers remove or restrict alogliptin products in favor of generic sitagliptin combinations, low-cost metformin regimens, SGLT2 inhibitors or GLP-1 therapies. This scenario can reduce Kazano demand even without a direct generic equivalent.
The third scenario is strategically important because it can depress revenue before formal patent expiry.
What geographic markets matter?
The United States is important for patent and regulatory analysis, but the commercial opportunity is broader.
United States
The U.S. market has high value per prescription but strong pressure from formulary management, patent challenges and newer diabetes classes. FDA approval and Orange Book listings control generic entry.
Japan
Japan has historically been more receptive to DPP-4 inhibitors than the United States. Alogliptin products, including combination products, may retain a longer commercial life where prescribing patterns favor oral agents and DPP-4 therapy.
Europe
European markets are price-sensitive and generally subject to centralized or national reimbursement decisions. Generic penetration and reference pricing limit long-term revenue.
Emerging markets
Lower-cost oral diabetes therapy can support continued demand, but local registration, pricing controls, procurement tenders and domestic manufacturing reduce margins. Licensing or contract manufacturing may be more valuable than direct branded commercialization.
What licensing and transaction opportunities exist?
The product is more suitable for a mature-brand or regional licensing transaction than for a premium strategic acquisition.
Potential transaction structures include:
- Geographic commercialization rights.
- Local manufacturing and supply agreements.
- Authorized generic arrangements.
- Portfolio acquisitions combining Kazano with Nesina or Oseni.
- Rights in emerging markets with established DPP-4 prescribing.
- Co-promotion agreements tied to primary-care portfolios.
Transaction value would depend on net sales, patent life, manufacturing cost, reimbursement access and the ability to bundle the product with other diabetes therapies. A buyer would generally discount the asset for declining class demand and limited differentiation.
What litigation affects alogliptin/metformin?
The principal legal issues are likely to involve:
- Orange Book patent validity and enforceability.
- ANDA Paragraph IV certifications.
- Infringement claims involving fixed-dose combination patents.
- Patent-term calculations.
- Authorized generic or supply arrangements.
- Product liability claims involving metformin-associated lactic acidosis or alogliptin-associated pancreatitis and heart-failure warnings.
No major public litigation campaign has established Kazano as a high-value patent battleground. The smaller market reduces the incentive for prolonged litigation unless a generic applicant anticipates rapid multi-market substitution.
Key Takeaways
- Alogliptin benzoate/metformin hydrochloride is the active combination in Kazano.
- The product was FDA-approved in 2013 and is a mature oral diabetes therapy.
- Its core commercial protection has weakened, while later combination patents may extend selected protection into the late 2020s.
- Kazano has no separately reported public revenue stream in Takeda’s standard financial disclosures.
- GLP-1 receptor agonists and SGLT2 inhibitors are the principal growth competitors.
- Generic risk includes both direct fixed-dose entry and separate-tablet substitution.
- Biosimilar risk does not apply because the product is a small-molecule drug.
- The patent estate provides some combination protection but limited long-term commercial leverage.
- Licensing value is concentrated in regional rights, low-cost supply and emerging-market distribution.
- The financial trajectory is mature to declining, with limited prospects for renewed branded growth.
FAQs
Is alogliptin/metformin the same as Janumet?
No. Kazano contains alogliptin and metformin, while Janumet contains sitagliptin and metformin. Both are DPP-4 inhibitor/metformin combinations but are not therapeutically identical.
Can metformin and alogliptin be prescribed separately?
Yes. Separate tablets can provide the same active ingredients, but the regimen may not be therapeutically or commercially interchangeable with the fixed-dose product without appropriate prescribing and pharmacy substitution rules.
Does alogliptin have biosimilar competition?
No. Alogliptin is a chemically synthesized small molecule. Competition proceeds through generic drug applications, not biosimilar applications.
Is Kazano still commercially important?
Kazano remains relevant as an established oral combination, but it is not a leading growth product. Its commercial importance is constrained by generic pressure and substitution by GLP-1 and SGLT2 therapies.
What is the main investment risk for alogliptin/metformin?
The main risk is simultaneous erosion from patent expiry, generic competition, declining DPP-4 utilization and payer preference for diabetes therapies with weight, cardiovascular or renal benefits.
References
- U.S. Food and Drug Administration. (2013). Kazano prescribing information. FDA.
- U.S. Food and Drug Administration. (2016). Nesina prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- Takeda Pharmaceutical Company Limited. (2024). Annual report 2024. Takeda.